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BACKGROUND 
For colorectal cancer screening, the predictive value of distal findings in the 
ascertainment of proximal lesions is not fully established. The aims of this study were to 
assess distal findings as predictors of advanced proximal neoplasia and to compare the 
predictive value of endoscopy alone vs. combined endoscopic and histopathologic data. 
 
METHODS 
Primary colonoscopy screening was performed in 2210 consecutive, average-risk adults. 
Age, gender, endoscopic (size, number of polyps), and histopathologic distal findings 
were used as potential predictors of advanced proximal neoplasms (i.e., any adenoma 
≥1 cm in size, and/or with villous histology, and/or with severe dysplasia or invasive 
cancer). Polyps were defined as distal if located in the descending colon, the sigmoid 
colon, or the rectum. Those in other locations were designated proximal. 
 
RESULTS 
Neoplastic lesions, including 11 invasive cancers, were found in 617 (27.9%) patients. 
Advanced proximal neoplasms without any distal adenoma were present in 1.3% of 
patients. Of the advanced proximal lesions, 39% were not associated with any distal 
polyp. Older age, male gender, and distal adenoma were independent predictors of 
advanced proximal neoplasms. The predictive ability of a model with endoscopic data 
alone did not improve after inclusion of histopathologic data. In multivariate logistic 
regression analysis, the predictive ability of models that use age, gender, and any 
combination of distal findings was relatively low. The proportion of advanced proximal 
neoplasms identified if any distal polyp was an indication for colonoscopy was only 
62%.  
 
CONCLUSIONS 
A strategy in which colonoscopy is performed solely in patients with distal colonic 
findings is not effective screening for the detection of advanced proximal neoplasms in 
an average-risk population. 
 
Reprint requests: Maite Betés Ibáñez, MD, PhD, Departamento de Digestivo, Clínica 
Universitaria de Navarra, 31080 Pamplona, Spain. 
INTRODUCTION 
 
Most colorectal cancers (CRC) develop from adenomas,1-3 which have a long, 
asymptomatic phase during which they are detectable and curable. Excision of 
colorectal adenomas reduces the incidence and the mortality of CRC.2,4-11 Therefore, 
CRC fulfills the criteria for benefit from screening.12
In 1996, the United States Preventive Services Task Force recommended screening of 
asymptomatic adults over 50 years of age with either flexible sigmoidoscopy (FS) or 
fecal occult blood tests (FOBT).13 These recommendations now are endorsed by the 
American Cancer Society,14 the World Health Organization,15 and by virtually all 
medical and surgical professional societies concerned with digestive diseases.16,17 A 
positive FS or FOBT result is an indication for colonoscopy. The continuing high 
mortality rates for patients with CRC, together with two large studies that demonstrate 
that FS fails to identify a substantial proportion of proximal lesions,18,19 have led many 
specialists to regard reliance on FS or FOBT alone as screening tests would be as wrong 
as mammography of a single breast in screening for breast cancer.12 A more detailed 
assessment of the costeffectiveness of alternative screening procedures20 has led to 
somewhat surprising conclusions that may favor colonoscopy as a primary test.21 
However, cost is a major limitation to screening, and a more thorough assessment of the 
predictive value of findings derived from FS to ascertain proximal lesions is needed 
before accepting colonoscopy as a primary screening modality. Direct comparisons of 
distal colon examinations vs. colonoscopy are useful to determine the potential 
additional benefit of examination of the entire colon. Most studies of the association 
between distal and proximal neoplasia are compromised by selection bias, including 
specific subgroups.22-35 Only studies wherein colonoscopy is offered as a primary 
screening procedure can appropriately address this issue. Currently, such data that are 
available derive from 3 studies that comprise relatively few cases36-38 and two large 
studies carried out in the United States.18,19 These large studies from the United States 
assess the usefulness of applying endoscopic and histopathologic findings in the distal 
colon to predict the likelihood of finding advanced proximal neoplasms. However, the 
value of endoscopic distal findings alone has not been compared with the predictive 
power of combined distal endoscopic and histopathologic data. Additional assessments 
of the relative importance and predictive value of the findings in the distal colon are 
required to guide clinical decision making. 
The primary aim of this study was to determine the diagnostic utility of distal colonic 
polyps for detecting advanced proximal colonic neoplasms (APN) in an average-risk 
population undergoing primary screening colonoscopy in a Mediterranean country. A 
secondary objective was to compare the predictive value of distal endoscopic findings 
alone with combined endoscopic and histopathologic data. 
 
 
PATIENTS AND METHODS 
 
Study design 
The study design was a retrospective analysis of asymptomatic, average-risk adults who 
were consecutively referred for screening colonoscopy to a university medical center 
endoscopy unit between 1988 and 1998. The study protocol was approved by a central 
human-rights committee, and written consent was required in all cases before 
colonoscopy. 
 
 
Patients 
Participants were included in the study if they presented to our clinic for a routine health 
evaluation and if they were considered to be at average risk for CRC after a medical 
interview. Our clinic is a private center that attracts patients from throughout Spain. The 
patients were referred to the endoscopy unit by specialists in internal medicine working 
in a health evaluation unit in our center. The policy for general health evaluation 
specifies colonoscopy for all patients older than 40 years. This policy was established in 
1988, before the publication of American Gastroenterological Association guidelines 
for CRC screening.16 Patients were excluded if they had undergone colonoscopy or 
sigmoidoscopy in the previous 5 years or reported hematochezia, change in bowel habit, 
or persistent abdominal or rectal pain. Other exclusion criteria were age less than 40 
years or greater than 90 years; iron deficiency anemia; weight loss; history of colon 
polyps or cancer; a first-degree relative with CRC; a history of breast or uterine cancer, 
inflammatory bowel disease, abdominal radiation, colonoscopy, or barium enema 
within the previous 5 years, performed for any indication; and use of anticoagulant 
medication. Patients who had an incomplete colonoscopy (2.2%) also were excluded 
from the analysis. 
 
Study procedures and definitions 
Colonoscopies were performed by staff gastroenterologists (7) or gastroenterology 
fellows (in their third or fourth year of fellowship) under the supervision of a staff 
gastroenterologist. All polyps visualized were removed by standard electrosurgical 
snare polypectomy. 
 
The following endoscopic findings were assessed: (1) location of the polyp(s) or cancer 
(endoscopist-estimated polyp location on withdrawal of the colonoscope by using 
landmarks and length of insertion tube within the patient), (2) number of polyps, and (3) 
polyp size (when seen intact or first removed). Size was confirmed by measuring the 
maximum diameter of the specimen when using an opened biopsy forceps as a visual 
guide. 
 
Polyps were defined as distal if located in the descending colon, sigmoid colon, or 
rectum; polyps in any other segment were designated proximal. Standard methods were 
used for histopathologic processing and analysis of colorectal polyps.39,40 All specimens 
were reviewed by a pathologist with special expertise in GI pathology. When there was 
uncertainty, especially for advanced lesions, the case was reviewed at an 
intradepartment meeting and a diagnosis was made by consensus. 
Patients with multiple polyps were categorized according to the polyp with largest 
diameter, the most atypical histology (villous, tubulovillous, tubular), and the most 
severe grade of dysplasia.41 
 
An ‘advanced neoplasm’ was defined as any adenoma 1 cm or greater in size, and/or 
with a villous (or tubulovillous) morphology, and/or with high-grade dysplasia or 
invasive cancer. Patients with intramucosal carcinoma or carcinoma in situ were 
classified as having high-grade dysplasia. Invasive cancer was defined as the invasion 
of malignant cells beyond the muscularis mucosa.39
 
Statistical analysis 
Logistic regression42 was used to identify independent predictors of APN (any adenoma 
≥1 cm in size, and/or with villous or tubulovillous morphology, and/or with highgrade 
dysplasia or invasive cancer). Univariate logistic regression analyses were performed to 
determine candi-date variables (i.e., those found to be significant at the level p < 0.25) 
for the subsequent multivariate logistic regression analysis, which was conducted to 
identify those variables with significant independent effects after adjusting for the 
effects of each of the other variables. Because the latter analysis was considered 
definitive, there was no need to correctp values to recognize that there was multiple 
testing of data arising from individual patients. Age, gender, and endoscopic and 
combined endoscopic and histopathologic data for distal polyps were entered as 
independent variables. Endoscopic data included two variables: number of polyps (0, 1, 
2, ≥3) and maximum size (no polyp, ≤5 mm, 6 9 mm, ≥10 mm). Combined endoscopic 
and histopathologic data included the following: histopathologic classification (non-
polyp, hyperplastic, nonadvanced adenoma ≤5 mm, nonadvanced adenoma >5 and <10 
mm, and advanced neoplasm) and number of adenomas (0, 1, 2, ≥3). Age and gender-
adjusted odds ratios (OR) for APN were calculated in two different logistic regression 
models that analyzed the following: (1) endoscopic distal findings and (2) combined 
distal endoscopic and histopathologic data. That the models adequately fit the data was 
checked with the Hosmer-Lemeshow goodness-of-fit test. The ability of the models to 
predict the existence of APN was assessed by estimation of the proportion of cases 
correctly predicted by each model, by calculating the area under the receiver operating 
characteristic (ROC) curve.43 
 
The diagnostic yield of different screening strategies was studied based upon distal 
findings by means of sensitivity, positive likelihood ratio, positive predictive value 
(PPV), and number of complete colonoscopies needed with each strategy.44
A brief meta-analyses encompassing this and other relevant studies18,19 was conducted 
(results are stated in the discussion section). Meta-analytic summary statistics were 
calculated based on the methods in Takkouche et al.45
 
 
RESULTS 
 
Screening colonoscopy was performed in 2210 consecutive average-risk patients (mean 
age 57.9; 74.6% men). Recruitment methods were routine health evaluation (1547 
patients, 70.0%) and followup of a stable medical problem (663 patients, 30.0%). There 
were 178 patients (8.05%) who were older than 70 years, and 445 (20.14%) were from 
40 to 49 years of age. Colonic polyps were detected in 825 (37.3%) and neoplastic 
lesions in 617 (28%) patients. Advanced neoplasms were found in 156 patients (7%). 
Invasive carcinoma was detected in 11 patients. All of these lesions were identified 
before there was apparent extracolonic spread of the disease. 
Among 56 patients (2.5%) with APN, 22 (39.3%) had no index distal polyp, 33 (58.9%) 
had at least one index distal adenoma, and 19 (33.9%) had at least one advanced distal 
neoplasm (Table 1). None of the 56 patients with APN in this study had hyperplastic 
distal polyps alone. In 144 patients, all distal colonic polyps were completely destroyed 
during resection and histopathologic data could not be obtained. Only one of these 
patients (1.8%) had an APN. 
 
Diagnostic yield of different screening strategies based upon distal findings 
The use of more flexible criteria for the definition of a positive sigmoidoscopy 
improved diagnostic sensitivity (for detection of patients with APN) (Table 2). 
However, the use of more flexible criteria also was associated with a larger proportion 
of patients undergoing sigmoidoscopy who are referred for subsequent colonoscopy. 
The proportion of patients with various distal findings who had APN (Table 3, PPV) 
serves to clarify the effectiveness of each screening model. 
 
The PPV for APN was higher in patients with advanced distal adenomas (16.0%: 95% 
CI[10.1, 24.1]) than in those without a distal adenoma (1.3%: 95% CI[0.8, 2.0]). Similar 
findings were observed when patients with distal polyps 10 mm or greater in diameter 
(PPV, 16.3%: 95% CI[10.1, 25.2]) were compared with patients without an index polyp 
(PPV, 1.4%: 95% CI[0.9, 2.1]). Screening strategies in which a colonoscopy would be 
indicated in either of these groups would detect 30.4% to 33.9% of patients with APN 
but would necessitate colonoscopy in only 4.7% to 5.4% of patients screened by FS 
(Table 2). 
 
The increase in sensitivity of screening strategies in which colonoscopy would be 
indicated for patients with small polyps or small nonadvanced distal adenomas (>5 and 
<10 mm) was related not only to the larger proportion of patients who would undergo 
colonoscopy (from 4.7%/5.4% to 12.2%/10.8%; Table 2), but also to a higher PPV in 
these groups (PPV, 6.7%; Table 3) compared with those without distal polyps. 
 
The PPV was virtually identical among patients with diminutive (≤5 mm) distal tubular 
adenomas (PPV, 1.2%: 95% CI[0.2, 4.6]) or diminutive (≤5 mm) polyps (PPV, 1.7%: 
95% CI[0.8, 3.7]) and those without any distal adenoma (PPV, 1.3%: 95% CI[0.8, 2.0]) 
or any distal polyp (PPV, 1.4%: 95% CI[0.9, 2.1]). The increase in sensitivity in 
screening strategies that indicated colonoscopy for these groups could be accounted for 
almost exclusively by the larger fraction of patients in these groups undergoing 
colonoscopy (respectively, 20.4% and 30.2%; Table 2). 
 
Predictors of advanced proximal neoplasms 
In univariate analyses, age, gender, and endoscopic and histopathologic characteristics 
of distal polyps were considered potential predictors of APN (p < 0.25). 
 
In multivariate analyses, age and gender were independent predictors of APN (p<0.05). 
For each year over 40 years of age, the risk increased by 5% (Table 4). The size of distal 
polyps was found to be the best endoscopic predictor of APN after adjustment for age 
and gender (Table 4, model A). Combining histopathologic and endoscopic findings 
(Table 4, model B) led to high ORs for advanced distal adenomas but also for 
nonadvanced small adenomas (6-9 mm in size). Distal lesions 5 mm or less in size 
(polyps in model A and adenomas in model B) were not found to be independently 
associated with a significantly greater risk of APN, unless they were multiple (≥3). 
 
The addition of any distal finding to age and gender increased the proportion of patients 
correctly predicted by the models (Table 5). It is noted that the areas under the ROCs 
for «any distal polyp greater than 5 mm in size" in the endoscopic model, for «any distal 
adenoma" in the combined model, and for maximum predictive potential in each of the 
endoscopic and combined models were significantly greater than the area under the 
ROC for the baseline (age and gender only) model. However, maximum area under the 
ROC was always lower than 80%, regardless of the number of variables included in the 
multivariate model. Negligible differences in the predictive value (area under ROC) 
were found when only endoscopic data were considered vs. when comparable 
histopathologic data were added to build the models. 
 
 
DISCUSSION 
 
This is the third study of the use of colonoscopy as a primary screening procedure in a 
large number of verage-risk adults18,19 and the first study conducted outside the United 
States. Because the study included consecutive colonoscopies in average-risk patients, 
who freely came to our clinic for a routine health evaluation, the results apply to 
decision making regarding the use of colonoscopy as a primary screening modality in 
the general population. 
 
Age and gender were independent risk factors for APN. For each year of age after 40 
years, the risk increased by 5% (after adjustment for gender and distal findings). This 
estimate is similar to that found in other studies.19 Our clinic is a private institution, and 
many of our patients have private health insurance. This may be the reason for so many 
men in the study population (74.6%). Men are known to have an increased age-related 
risk for colon neoplasia. Over a lifetime, women have a risk of CRC similar to that of 
men (because they live 5-7 years longer). Although men are known to be at increased 
risk of colorectal neoplasia, specific differences regarding APN have not been fully 
established.19,46,47 
 
Information on the prevalence of isolated APN was not available until recently.18,19 In 
the present study, patients with no distal adenomas had a risk of APN of 1.3%, a 
proportion similar to that reported recently for the United States. Consistent with other 
studies,18,19,48-52 the data from the present study show that 40% of APN (22 of 56) would 
not have been detected if only the distal colon had been examined, even if FS were 
followed by colonoscopy when any index distal polyp (hyperplastic or adenoma) was 
found (Table 1). 
 
Three studies have evaluated the predictive ability of lesions in the distal colon for the 
risk of APN (Table 6). Summarizing the sensitivity of these  studies, 61.1% of patients 
with APN (95% CI[54.9, 68.0]) had at least one index distal polyp, and 50.1%: 95% 
CI[43.8, 57.4] had at least one index distal adenoma. 
 
To estimate the probability of APN, considering distal polyp characteristics, age, and 
gender together increases the predictive ability, but the area under the ROC was lower 
than 80% for all models that stratify patients according to different distal findings. The 
area under the curve can be directly interpreted as the predicted probability of a test to 
classify correctly a pair of patients, one with and one without the disease (APN in the 
present study). This highlights the limitations of findings at FS in predicting APN. The 
predictive ability of models that included endoscopic data alone was similar to that 
observed in models that also included histopathologic data. These results support the 
screening strategy proposed by Stern et al.,53 which provides comprehensive CRC 
screening in a single visit by converting from sigmoidoscopy to colonoscopy, 
depending on distal endoscopic findings. This strategy may reduce the costs of 
traditional endoscopic screening.54 
 
Imperiale et al.19 found a significant association between hyperplastic distal polyps and 
APN. Our results, however, confirm those of other studies18,32,55-59 that show that 
hyperplastic polyps are not predictors of APN. Results differ when the predictive value 
of different characteristics of distal adenomas were studied in multivariate anal  
yses.24-27,29,33-35,46,58,60-64 The results of the current study are consistent with those of 
previous studies that demonstrate the importance of advanced distal neoplasms as a 
marker of APN. In fact, pooling of our results with those of previous studies18,19 shows 
homogeneity for tubular adenoma (combined OR 2.96: 95% CI[2.16, 4.05]) and 
advanced neoplasms (combined OR 6.43: 95% CI[4.34, 9.52]). Our data show that 
patients with diminutive tubular adenomas (≤5 mm) at FS are not at significantly 
increased risk for APN. If these patients were excluded, the sensitivity of distal 
examination for detection of APN would decrease to less than 50% (48.2% in the 
present study: 95% CI[35.1, 61.3]). 
 
The present study has some limitations. First, although the procedures performed 
remained essentially unchanged over the 10 years of the study, some heterogeneity 
across time can be expected. Second, there is a possibility of self-selection bias, because 
the study included patients who exhibited healthseeking behavior. However, there is not 
sufficient evidence that such behavior modifies the effect of the variables studied. Third, 
distal colonoscopic findings were used as a surrogate for findings at sigmoidoscopy. 
The descending colon may not be reached with a sigmoidoscope, or the examination 
may be limited by suboptimal bowel preparation. Therefore, the present study provides 
an estimate of the maximum predictive ability of sigmoidoscopy. Fourth, the data alone 
may not be sufficient for deciding which technique is best for primary CRC screening. 
Other information, such as the expense and complications of colonoscopy and the 
natural history of advanced neoplasms, also are relevant. The use of colonoscopy to 
screen asymptomatic individuals for CRC is feasible and may be the best alternative for 
identification of patients who may benefit from early detection and removal of 
potentially malignant lesions. The data from the present study highlight some of the 
limitations of FS as a primary CRC screening test. The study found that many patients 
with APN would not be identified by FS and that the risk of APN is associated with 
increasing age and male gender. If a primary goal of screening is the detection and 
removal of advanced adenomas, colonoscopy offers more effective screening than 
sigmoidoscopy. 
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Table 1. Frequency of distal colonic polyps in patients with advanced           
proximal neoplasia 
 
Proximal findings 
Advanced proximal 
neoplasms (n = 56, 2.5%) 
N (%) 
Distal findings (n = 2210) 
No polyps or benign polyps (1553) 22 (39.3) 
Hyperplastic polyps alone (63) 0 (0) 
Fulgurated diminutive polyps alone (144)* 1 (1.8) 
Nonadvanced adenomas (331) 14 (25) 
Advanced neoplasiat (119)# 19 (33.9) 
*Fulgurated diminutive polyps: in 144 patients in which diminutive polyps only 
were found in the distal colon, these polyps were fulgurated during excision 
with polypectomy snare. Therefore, their histopathology could not be 
ascertained. 
#Definition of advanced neoplasia: any adenoma $10 mm, and/or with villous 
component (tubulovillous or villous adenoma), and/or high-grade dysplasia or 
invasive cancer. 
 
 
 
 
 
Table 2. Predictive value of distal colonic findings for advanced proximal neoplasia 
Screening strategies based on 
distal colonic findings Sensitivity for APN LR(+) for APN 
Patients undergoing
colonoscopy 
Criteria for a positive distal 
endoscopic examination % (95% CI) % (95% CI) % (95% CI) 
Endoscopic distal findings    
Any polyp ≥10 mm 30.4 (19.2-44.3) 7.5 (2.35-12.69) 4.7 (3.9-5.7)
Any polyp >5 mm 50.0 (36.5-63.5) 4.5 (4.2-8.52) 12.2 (10.8-13.6)
Any distal polyp 62.5 (48.5-74.8) 2.1 (0.0-4.91) 30.2 (28.7-32.6)
Endoscopic and histopathologic 
distal findings    
Any advanced distal neoplasia 33.9 (22.2-47.9) 7.3 (2.21-12.41) 5.4 (4.5-6.4)
Any distal adenoma >5 mm 48.2 (35.1-61.3) 5.2 (0.83-9.51) 10.8 (9.5-12.1)
Any distal adenoma 58.9 (45.0-71.6) 3.0 (0.0-6.41) 20.4 (18.7-22.1)
Primary screening with 
olonoscopy 100  100 
APN, Advanced proximal neoplasia; LR, likelihood ratio; CI, confidence interval. 
 
 
Table 3. Positive predictive value for advanced proximal neoplasms                           
according to different distal findings
Combined endoscopic and pathologic data Only endoscopic data 
Distal findings PPV % (95% CI) Distal findings PPV % (95% CI)
Advanced neoplasms 16.0 (10.1-24.1) Polyps ≥10 mm 16.3 (10.1-25.2) 
Nonadvanced adenomas 
 
>5 mm and <10 mm 6.7 (2.2-11.1) Polyps >5 and <10 mm 6.7 (3.5-11.9) 
Nonadvanced adenomas ≤5 mm 1.2 (0.2-4.6) Polyps ≤5 mm 1.7 (0.8-3.7) 
No distal adenomas 1.3 (0.8-2.0) No polyps 1.4 (0.9-2.1) 
PPV, Positive predictive value; CI, confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Risk of advanced proximal neoplasia according to distal endoscopic and histopathologic findings; 
multivariate models  
Model A: age, gender and endoscopic assessment 
Risk of APN Variable 
% with APN Adjusted OR (95% CI)
Age (for each year older) 1.05 (1.02, 1.09)
Gender 
Female 1.6 1 (referent)
Male 2.9 1.36 (0.64, 2.91)
Endoscopic assessment 
No distal polyps 1.4 1 (referent)
Distal polyps (maximum size) 
≤5 mm 1.7 1.01 (0.40, 2.57)
6-9 mm 6.7 3.49 (1.43, 8.51)
≥10 mm 16.3 9.28 (4.08, 21.10)
Distal polyps (number) 
No distal polyps 1.4 1 (referent)
1 distal polyp 3.8 see “maximum size”
2 distal polyps 4.3
≥3 distal polyps 9.5 1.80 (0.80, 4.06)
Note: In a patient with two distal polyps, the largest of which is >10 mm, the OR for APN would be 1.06 
x 9.28.  
APN, Advanced proximal neoplasia; OR, odds ratio; CI, confidence interval. 
Model B: age, gender, endoscopic and histopathologic assessment 
 Risk of APN 
Variable (distal findings) % with APN Adjusted OR† (95% CI) 
Combined endoscopic and histopathologic assessment
No distal polyps 1.4 1 (referent)
Hyperplastic only 0.0 0.01 (—)
Fulgurated polyps only 0.7 0.45 (0.06, 3.38)
Adenomas (type) 
Nonadvanced 
≤5 mm 2.8 1.52 (0.58, 3.97)
6-9 mm 6.7 3.00 (1.78, 7.68)
Advanced ‡ 16.0 7.30 (3.28, 16.25)
Adenomas (number) 
1 adenoma 4.9 see ‘‘type’’
2 adenoma 9.6 1.81 (0.74, 4.44)
≥3 adenomas 19.1 2.65 (1.03, 6.86)
†Odds ratios shown in each model are adjusted for age, gender, and all other variables presented in the 
model. 
‡Adenoma ≥10 mm, with villous component or with severe dysplasia or invasive cancer. 
  
Table 5. Prediction of advanced proximal neoplasms according to different 
screening strategies based upon distal findings. 
Variables in the model Area under the ROC    curve, % (95% CI) 
Baseline model: age and gender only 66.4 (61.6, 71.1) 
Endoscopic models (adjusted for age and 
gender)  
Any distal polyp 73.8 (67.3, 80.3) 
Any distal polyp >5 mm 78.2 (71.8, 84.7) 
Any distal polyp ≥10 mm 74.6 (67.4, 81.7) 
Maximum predictive potential (size and 
number of distal polyps) 78.6 (72.1, 85.1) 
Combined endoscopic and histopathologic 
models (adjusted for age and gender)  
Any distal adenoma or cancer 77.0 (70.6, 83.3) 
Any distal adenoma >5 mm 77.7 (70.8, 84.7) 
Any advanced distal neoplasm 75.6 (68.6, 82.6) 
Maximum predictive potential (size, 
histopathology, dysplasia, and number of 
distal neoplasms) 
79.7 (73.1, 86.2) 
ROC, Receiver operating characteristic; CI, confidence interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Comparison of the studies of the sensitivity of sigmoidoscopy in the 
detection of advanced neoplasms in colon 
Patients with APN                
Study Total Any distal polyp 
Any distal 
adenoma 
Any distal 
advanced 
N 
        N Sensitivity, % (95% CI) 
Lieberman (19) 128 80 62 27 
  62.5 (53.5-70.8) 48.4 (39.6-57.4) 21.1 (14.6-29.4) 
Imperiale (20)* 50 27 19 7 
  54.0 (39.5-67.9) 33.0 (25.0-52.8) 14.0 (6.3-27.4) 
Present study 56 35 33 19 
  62.5 (48.5-74.8) 58.9 (45.0-71.6) 33.9 (22.2-47.9) 
Summary of 
sensitivity 
(pooled estimate) 
 61.1 (54.9-68.0)† 50.1 (43.8-57.4)‡ 24.4 (14.8-36.1)§
APN, Advanced proximal neoplasms (≥10 mm and/or villous and/or severe 
dysplasia or invasive cancer); CI, confidence interval. 
*In the study of Imperiale et al., size ≥10mm was not considered a feature of 
advanced adenoma. 
A lack of significant heterogeneity in the Q test was taken as indicating that a 
fixed effect model was appropriate for the summing-up. Test for heterogeneity 
(pooled estimate): 
Sensitivity†, p = 0.64; Sensitivity‡, p = 0.13; Sensitivity§, p = 0.06. 
 
